STAT Plus: Pharmalittle: Will AstraZeneca bid for Gilead?; university terminates researcher over Covid-19 papers
Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing or rejuvenating, given current circumstances. In any event, the usual routine — such as it is — of deadlines, online meetings, and the like has predictably returned. So what better way to cope than with a cup of delicious stimulation. Our choice today, for those tracking this sort of thing, is cinnamon dolce. Please feel free to join us. Meanwhile, here are a few tidbits to get you going. Hope your day goes well, and do keep in touch. …
AstraZeneca (AZN) made a preliminary approach to Gilead Sciences (GILD) about a potential merger, Bloomberg News reports. AstraZeneca informally contacted Gilead last month to gauge interest in a possible deal but did not specify terms. Gilead has discussed the idea with advisers, but no decisions have been made on how to proceed. “Does AstraZeneca really need this? We argue no,” wrote Wolfe Research analyst Tim Anderson to investors. And The Times of London says AstraZeneca has since cooled on the idea.
Continue to STAT Plus to read the full story…
